In this issue:
Gut microbiome alterations in CU
Barzolvolimab in CSU
CU in Cape Town, South Africa
All-cause mortality in adult CSU
Addictive behaviours in CSU
Real-world serum biomarkers to predict omalizumab response in CSU
IgE as potential predictive biomarker of omalizumab response in refractory CSU
CSU patients who are unable to cease omalizumab
Necessity of skin prick testing in paediatric CU
Efficacy & safety of omalizumab in CSU
Please login below to download this issue (PDF)